Abstract:He Zhang, Weimin Kong, Chao Han, Tingting Liu, Jing Li, Dan Song Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Weimin Kong Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing Maternal and Child Health Care Hospital, Capital Medical University, Qihelou Street, Dongcheng District, Beijing, 100006, People's Republic of China Tel +86 18801273620 Email Purpose: This study aimed to investigate the association of metabolic factors with endometrial atypical hyperplasia and endometrial cancer, and to develop a nomogram model to predict the risk of developing endometrial cancer. Patients and Methods: We collected data of patients with endometrial atypical hyperplasia and endometrial cancer as the case group and then selected patients with simple hyperplasia or polypoid hyperplasia of the endometrium during the same period as the control group using the age-matched method. Laboratory results of metabolic factors were retrieved from the clinical data of the two groups of patients. Multivariable logistic regression analysis was used to determine the risk factors associated with endometrial malignant hyperplasia and to develop a nomogram prediction model of risk factors associated with endometrial malignant hyperplasia. Discrimination, calibration, and clinical usefulness of the prediction model were assessed using the C-index, calibration plot, and decision curve analysis. Results: Predictors included in the column line graph model were age, hypertension, diabetes, BMI, uric acid, and hyperlipidemia. We calculated the C-index of the model and performed bootstrap validation. Our nomogram model had good discriminatory power and was well calibrated. Decision curve analysis was also used to guide the practical application of this column line graph model. Conclusion: The development of endometrial malignant hyperplasia is significantly associated with metabolic factors: BMI > 25, hyperuricemia, and hyperlipidemia are the main risk factors. Hypertension, hyperglycemia and elevated CA199 were also associated with the development of endometrial malignant hyperplasia. The nomogram prediction model based on physical examination and laboratory testing developed in this study can be used as a rapid method for predicting the risk of endometrial malignancy development and screening for risk factors in a population of women with metabolism-related high-risk factors. Keywords: risk factors, gynecologic oncology, predictors, nomogram Endometrial cancer is one of the most common gynecological malignancies. The latest cancer statistics from the American Cancer Society show that in 2020 the number of new cases of endometrial cancer in the United States was 65,620, and the number of deaths was 12,590. The incidence of malignant endometrial tumors in women ranked fourth, and the incidence of death from endometrial cancer ranked sixth. 1 Endometrial atypical hyperplasia (EAH) is a precancerous lesion of endometrial cancer. 2 The mechanisms of endometrial cancer and endometrial atypical hyperplasia pathological process are complex and polycentric in time and space. In recent years, the development of early diagnostic surgery and radiotherapy has improved patient outcomes to a great extent. However, the diagnosis and treatment of endometrial lesions at an early stage, surgery to preserve reproductive function, and research into the treatment of advanced and recurrent patients remain promising. Metabolic syndrome (MS) is defined as a complex of metabolic risk factors associated with a variety of diseases, including cardiovascular disease and diabetes. 3 The main components of metabolic syndrome are obesity, diabetes or impaired glucose tolerance, dyslipidemia, and hypertension. Furthermore, metabolic syndrome includes insulin resistance, hyperuricemia, and microalbuminuria. Recent studies have found that the incidence of endometrial cancer is increasing with the rise in the prevalence of metabolic diseases (eg, obesity, hypertension, and diabetes). 4 To this end, we collected case data from the Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, to retrospectively analyze metabolic parameters in patients with endometrial hyperplasia and malignant lesions, evaluate relevant metabolic risk factors for the development of endometrial malignant hyperplasia, and establish a nomogram prediction model to predict the risk of endometrial malignant hyperplasia. Research approval was obtained from Beijing Obstetrics and Gynecology Hospital, Capital Medical Univ -Abstract Truncated-

Should body mass index replace age to drive the decision for endometrial sampling in premenopausal women with abnormal uterine bleeding?

Association of body mass index with early age at diagnosis of endometrial intraepithelial neoplasia

Body Mass Index Is Positively Associated with Endometrial Cancer in Chinese Women, Especially Prior to Menopause

The Association Between Metabolic Abnormality and Endometrial Cancer: a Large Case-Control Study in China.

Body mass index in relation to ovarian cancer survival.

Do Obesity and Age Effect the Clinicopathological Features and Survival Outcomes in Premenopausal Women with Endometrial Cancer?

Investigation on risk factors of endometrial carcinomas and atypical endometrial hyperplasia

The Role of Endometrial Sampling before Hysterectomy in Premenopausal Women with Abnormal Uterine Bleeding

Can adjusting BMI for age and sex provide for a better predictor of colonic neoplasia?

The association between body mass index and molecular subtypes in endometrial carcinoma

Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma

BMI and breast cancer risk around age at menopause

When is it necessary to perform biopsy in asymptomatic postmenopausal women with incidental finding of thickened endometrium?

Clinical factors as prognostic variables among molecular subgroups of endometrial cancer

Risk factors for atypical hyperplasia or endometrial cancer in premenopausal women aged ≤ 45 years with abnormal uterine bleeding

46. Endometrial Intraepithelial Neoplasia in a 14-year-old Adolescent Presenting with Heavy Menstrual Bleeding

Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis

Influence of body mass index on prognosis in gynecological malignancies

Correlation of Metabolic Factors with Endometrial Atypical Hyperplasia and Endometrial Cancer: Development and Assessment of a New Predictive Nomogram

Adult Body Mass Index and Risk of Ovarian Cancer by Subtype: a Mendelian Randomization Study.

A Review of the Risk Factors Associated with Endometrial Hyperplasia During Perimenopause